Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ibandronate in metastatic bone pain.

Axel Heidenreich1, Carsten Ohlmann, Jean-Jacques Body

  • 1Division of Oncological Urology, Department of Urology, University of Cologne, Germany.

Seminars in Oncology
|October 19, 2004
PubMed
Summary

Ibandronate effectively reduces metastatic bone pain for up to two years, improving patient quality of life. This bisphosphonate offers sustained relief, potentially decreasing the need for analgesics and radiotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aktuelle Urologie·2026
Same author

Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.

BJU international·2026
Same author

[From limited options to individualized strategies: advances in the treatment of bladder cancer].

Urologie (Heidelberg, Germany)·2026
Same author

[Critical self-assessment as an instrument to optimize surgical strategies in the management of upper urinary tract urothelial cancer].

Urologie (Heidelberg, Germany)·2026
Same author

<i>NECTIN4</i> Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

European urology open science·2026
Same author

[Multidisciplinary cancer therapy-more important than ever].

Urologie (Heidelberg, Germany)·2026

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bone pain is a common and debilitating complication of metastatic bone disease.
  • Current treatments like bisphosphonates offer limited duration of relief.

Purpose of the Study:

  • To evaluate the efficacy and duration of bone pain relief provided by ibandronate in patients with metastatic bone disease.
  • To assess the impact of ibandronate on patient quality of life and functioning.

Main Methods:

  • Phase III studies involving intravenous (6 mg) and oral (50 mg) ibandronate compared to placebo.
  • Open, nonrandomized studies using intensive, high-dose intravenous ibandronate in patients with opioid-resistant bone pain.

Main Results:

  • Ibandronate significantly reduced bone pain below baseline levels within 6 weeks, with sustained reductions over 96 weeks (P < or =.001).
  • Both intravenous and oral ibandronate demonstrated rapid relief of moderate-to-severe metastatic bone pain.
  • Improvements in quality of life and patient functioning were observed.

Conclusions:

  • Ibandronate provides effective and sustained long-term relief from metastatic bone pain.
  • This clinical benefit may reduce healthcare resource utilization by decreasing analgesic and radiotherapy requirements.

Related Experiment Videos